Insulin-specific B-cell receptor (Insulin-specific BCR) (Insulin-specific BCR)

Insulin-specific B-cell receptors (BCRs) are membrane-bound immunoglobulins on B lymphocytes that specifically bind to insulin, a primary autoantigen in Type 1 Diabetes (T1D) (Smith et al., 2017, Journal of Immunology). In T1D, these insulin-reactive B cells escape immune tolerance and act as essential antigen-presenting cells that activate autoreactive T cells, leading to the destruction of pancreatic beta cells (Thomas et al., 2010, Diabetes). The presence of insulin autoantibodies (IAA), the secreted form of these BCRs, is a key clinical biomarker for the onset of islet autoimmunity (Pescovitz et al., 2009, NEJM). While general B-cell depletion therapies like Rituximab have shown some efficacy in preserving C-peptide levels in new-onset T1D, they carry risks of systemic immunosuppression (Pescovitz et al., 2009, NEJM). Consequently, research is focused on antigen-specific therapies, such as insulin-conjugated toxins or nanoparticles, designed to selectively target and eliminate only the insulin-specific BCR-bearing cells (Sosenko et al., 2015, Diabetes Care).

Other names

Insulin-reactive B-cell receptorAnti-insulin B-cell receptorInsulin-binding B-cell receptorInsulin-specific BCR

Depletion of B-cell populations, including those expressing insulin-specific receptors, to reduce autoantigen presentation and the production of insulin autoantibodies.